Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
216.12
-12.60 (-5.51%)
At close: Aug 6, 2026, 4:00 PM EDT
216.12
0.00 (0.00%)
After-hours: Aug 6, 2026, 6:16 PM EDT
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 28 analysts polled by S&P Global, Alnylam Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $375.76. The average 1-year stock price forecast is 73.87% higher than the current stock price, while the lowest is $230 (+6.42%) and the highest is $536 (+148.01%).
Price Target: $375.76 (+73.87%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 14 | 15 | 14 | 14 | 15 |
| Buy | 6 | 6 | 7 | 7 | 8 | 7 |
| Hold | 8 | 8 | 8 | 8 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 28 | 28 | 30 | 29 | 28 | 28 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI | Evercore ISI | Buy Maintains $400 → $325 | Buy | Maintains | $400 → $325 | +50.38% | Aug 5, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $375 | Buy | Maintains | $375 | +73.51% | Aug 5, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $485 → $455 | Buy | Reiterates | $485 → $455 | +110.53% | Aug 4, 2026 |
| Truist Financial | Truist Financial | Buy Reiterates $410 → $315 | Buy | Reiterates | $410 → $315 | +45.75% | Aug 4, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $429 | Buy | Reiterates | $429 | +98.50% | Aug 3, 2026 |
Financial Forecast
Revenue This Year
5.51B
from 3.71B
Increased by 48.38%
Revenue Next Year
7.04B
from 5.51B
Increased by 27.68%
EPS This Year
8.97
from 5.08
Increased by 76.48%
EPS Next Year
12.55
from 8.97
Increased by 40.01%
EPS and Forward PE are based on non-GAAP adjusted numbers.